#United States #New York #Class Action #Levi & Korsinsky #Unicycive Therapeutics

Join the Class Action Suit Against Unicycive Therapeutics, Inc.

On October 14, 2025, the opportunity for investors to join a class action lawsuit against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) will close. The firm Levi & Korsinsky, known for its accomplishments in securities fraud cases, is leading this class action aimed at compensating investors who have suffered losses due to recent allegations of misleading statements made by the company.

Class Action Details

The class action lawsuit targets investors who were affected by potential securities fraud during the period of March 29, 2024, to June 27, 2025. The allegations suggest that Unicycive Therapeutics overstated its readiness to meet FDA manufacturing compliance protocols and misrepresented the prospects of its new drug application for oxylanthanum carbonate. Such overstated claims led to significant financial losses for shareholders.

Important Deadlines and Contact Information

If you are an Unicycive investor, you must act swiftly. The deadline to request appointment as a lead plaintiff in this case is October 14, 2025. However, it is important to note that participation in the class action does not require individuals to serve as a lead plaintiff, allowing all affected investors to seek compensation without incurring out-of-pocket costs.

Levi & Korsinsky urges those who believe they may qualify to contact them either via email at [email protected] or by phone at (212) 363-7500. More information can be found through their website.

Why Choose Levi & Korsinsky?

For over 20 years, Levi & Korsinsky has established a strong reputation by successfully winning numerous high-stakes cases and recovering hundreds of millions for affected shareholders. Their team of over 70 professionals is dedicated to providing expert legal support, specifically tailored for investors embroiled in complex securities litigation.
They’ve consistently ranked in the ISS Securities Class Action Services' Top 50 Report as one of America's leading securities litigation firms, reflecting their expertise and commitment to justice.

Conclusion

This class action represents an important step for investors looking to reclaim their losses amidst troubling allegations against Unicycive Therapeutics. Levi & Korsinsky stands ready to advocate for affected parties, ensuring they are not alone in this fight for accountability and fairness.